"Pharmaceutical companies using CSOs must renew contracts
By Kim, Jin-Gu | translator Hong, Ji Yeon
24.11.26 05:09:24
가나다라
0
The KPBMA hosts the 'Ethical Management Workshop for the Second Half of 2024'
Attorney Park Jong-cheol says, "Excessive compensation·guaranteed margins are in violation of the law"
"With the implementation of the CSO reporting system, oversight responsibilities ↑…diversifying transactions may be necessary"
Based on the Contract Sales Organization (CSO) reporting system implemented last month, pharmaceutical companies must be aware of potential legal risks. Pharmaceutical companies using CSOs must sign contracts with companies that have completed registration and renew existing contracts to align with the timeline following reporting.
▲The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) hosted the
On November 22, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) hosted the 'Ethical Management Workshop for the Second Half of 2024' at the Mondrian Seoul Itaewon. During the workshop, Attorney Park Jong-cheol from the law firm Hwawoo advised as such. Over 300 compliance officers (CP) from the pharmaceutical industry, in-person and online, have parti
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)